The Difference Between Carfilzomib and Ixazomib

Carfilzomib (Carfilzomib) and ixazomib (Ixazomib) are both drugs used to treat multiple myeloma (Multiple Myeloma), but they have some significant differences in chemical structure, working mechanism, usage and side effects. Below is a detailed comparison of these two drugs to better understand their similarities and differences.

1.Chemical structure:

Carfilzomib: Carfilzomib is a protease inhibitor and belongs to the subclass of proteasome inhibitors. Its chemical structure is that of a compound called cerebroside, commonly sold under the trade name Kyprolis. Cerebroside inhibits protein degradation in the proteasome, leading to tumor cell death.

Ixazomib: Ixazomib is also a protease inhibitor and is a similar drug to proteasome inhibitors. Its chemical structure is different from that of carfep, and it is a new type of isoprenodeoxynucleoside, commonly sold under the trade name Ninlaro. Ixazomib also works against multiple myeloma by interfering with proteasome function.

2.Working mechanism:

Carfilzomib: Carfilzomib kills cancer cells by specifically inhibiting the function of the proteasome. It interacts with specific proteasome subunits to prevent protein degradation, leading to the death of multiple myeloma cells. It affects the proteasome more strongly than ixazomib.

Ixazomib: Ixazomib also interferes with the survival and proliferation of cancer cells through proteasome inhibition, but it works in a slightly different way. Ixazomib binds to subunits in the proteasome and inhibits protein degradation. It may have a milder inhibitory effect relative to carfilzomib.

3.Usage:

Carfilzomib: Carfilzomib is usually given as an intravenous injection. It is often used along with other drugs, such as immune modulators and hormone therapy, as first-line treatment or as a relapse treatment for multiple myeloma.

Ixazomib: Ixazomib is an oral drug that patients can take orally as capsules. This makes ixazomib more convenient and does not require regular intravenous administration.

4.Side effects:

Carfilzomib: Carfilzomib may cause a range of side effects, including cardiotoxicity, pulmonary toxicity, hypertension, bleeding, fatigue, nausea, vomiting, diarrhea, anemia and renal impairment. Therefore, patients' health needs to be closely monitored while using carfilzomib.

Ixazomib: Ixazomib's side effects are relatively mild and include nausea, vomiting, diarrhea, fatigue, anemia, and rash. It carries a lower risk of cardiac and pulmonary toxicity than carfilzomib.

5.Approval status:

Carfilzomib: Carfilzomib has been approved by many countries, including the US Food and Drug Administration (FDA) for the treatment of multiple myeloma.

Ixazomib: Ixazomib has also been approved by the FDA as a treatment option for relapsed multiple myeloma. It is usually used when a patient is resistant to other treatments or cannot tolerate other drugs.

To sum up, carfilzomib and ixazomib are two important drugs used to treat multiple myeloma. They have some significant differences in chemical structure, usage, side effects and working mechanism. The choice of treatment options often depends on the patient's specific circumstances, including the severity of the disease, response to other treatments, and the individual's health. The doctor will decide which drug to use based on these factors to achieve the best therapeutic effect. Taken together, both drugs play a key role in the treatment of multiple myeloma, providing patients with hope and the opportunity to improve their quality of life.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. In foreign countries, the original drug of carfilzomib is mainly available, and the cheaper version is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.